Innovent Biologics, Inc. has announced its plans to present a range of clinical and preclinical results related to Mazdutide and its next-generation obesity and metabolic pipeline at the upcoming 2026 American Diabetes Association (ADA) Scientific Sessions. The company, which operates in both San Francisco and Suzhou, China, is recognized for its commitment to developing innovative biopharmaceutical solutions. This presentation is expected to highlight the advancements and findings from their ongoing research efforts in the field of obesity and metabolic disorders. Further details regarding the specific studies and results to be shared will be disclosed during the sessions.
Related Articles
Don't miss out on breaking stories and in-depth articles.